Systemic treatment for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new prom...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Manushi, Arain, Abeer, Jin, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Medical Association 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160617/
https://www.ncbi.nlm.nih.gov/pubmed/30276361
http://dx.doi.org/10.1016/j.cdtm.2018.08.003
_version_ 1783358803664699392
author Aggarwal, Manushi
Arain, Abeer
Jin, Zhaohui
author_facet Aggarwal, Manushi
Arain, Abeer
Jin, Zhaohui
author_sort Aggarwal, Manushi
collection PubMed
description Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies.
format Online
Article
Text
id pubmed-6160617
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Chinese Medical Association
record_format MEDLINE/PubMed
spelling pubmed-61606172018-10-01 Systemic treatment for hepatocellular carcinoma Aggarwal, Manushi Arain, Abeer Jin, Zhaohui Chronic Dis Transl Med Perspective Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies. Chinese Medical Association 2018-09-17 /pmc/articles/PMC6160617/ /pubmed/30276361 http://dx.doi.org/10.1016/j.cdtm.2018.08.003 Text en © 2018 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Perspective
Aggarwal, Manushi
Arain, Abeer
Jin, Zhaohui
Systemic treatment for hepatocellular carcinoma
title Systemic treatment for hepatocellular carcinoma
title_full Systemic treatment for hepatocellular carcinoma
title_fullStr Systemic treatment for hepatocellular carcinoma
title_full_unstemmed Systemic treatment for hepatocellular carcinoma
title_short Systemic treatment for hepatocellular carcinoma
title_sort systemic treatment for hepatocellular carcinoma
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160617/
https://www.ncbi.nlm.nih.gov/pubmed/30276361
http://dx.doi.org/10.1016/j.cdtm.2018.08.003
work_keys_str_mv AT aggarwalmanushi systemictreatmentforhepatocellularcarcinoma
AT arainabeer systemictreatmentforhepatocellularcarcinoma
AT jinzhaohui systemictreatmentforhepatocellularcarcinoma

Ejemplares similares